|
1 Gilbert C, Muhit M. Twenty years of childhood blindness: What have we learnt[J]? Community Eye Health, 2008, 21(67)：46-47.
|
|
2 Silverman WA. A cautionary tale about supplemental oxygen: The albatross of neonatal medicine[J]. Pediatrics, 2004, 113(2): 394-396.
|
|
3 Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: A national survey of recent practices[J]. J Perinatol, 2004, 24: 164-168.
|
|
4 Hubbard GB. Surgical management of retinopathy of prematurity[J]. Curr Opin Ophthalmol, 2008, 19(5): 384-390.
|
|
5 Good WV. The cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: One-year outcome-Structure and function[J]. Trans Am Ophthalmol Soc, 2004, 102: 233-250.
|
|
6 Zhang ZH, Jiang L, Qiao LX. Expression of mRNA of vascular endothelial growth factor in a rat model of hyperoxia-induced retinopathy[J]. Chin J Contemporary Pediatr, 2007, 9(4): 371-374.
|
|
7 Shih SC, Ju M, Liu N, et al. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity[J]. J Clin Invest, 2003, 112(1)：50-57.
|
|
8 Konopatskaya O, Churchill AJ, Harper SJ, et al. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice[J]. Mol Vis, 2006, 12: 626-632.
|
|
9 Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease[J]. Curr Opin Ophthalmol, 2007, 18(6): 502-508.
|
|
10 Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: Amorphologic study[J]. Arch Ophthalmol, 2008, 126: 1161-1163.
|
|
11 Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II[J]. Retina, 2008, 28(6): 831-838.
|
|
12 Sears JE. Anti-vascular endothelial growth factor and retinopathy of prematurity[J]. Br J Ophthalmol, 2008, 92: 1437-1438.
|
|
13 Engstrom E, Niklasson A, Wikland KA, et al. The role of maternal factors, postnatal nutrition, weight gain, and gender in regulation of serum IGF-1 among preterm infants[J]. Pediatr Res, 2005, 57(4): 605-610.
|
|
14 Hellstrom A, Engstrom E, Hard AL, et al. Postnatal serum insulin like growth factor-1 deficiency is associated with retinopathy of prematurity and other complications of premature birth[J]. Pediatrics, 2003, 112(5): 1016-1020.
|
|
15 Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization[J]. J Clin Invest, 2003, 111(12): 1835-1842.
|
|
16 Kermorvant-Duchemin E, Sennlaub F, SirinyanM, et al. Transarachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneratio[J]. Nat Med, 2005, 11: 1339-1345.
|
|
17 SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina[J]. Prog Retin Eye Res, 2005, 24(1): 87-138.
|
|
18 Calder PC. Polyunsaturated fatty acids and inflammation[J]. Prostaglandins Leukot Essent Fatty Acids, 2006, 75(3): 197-202.
|
|
19 Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of ω-3-polyunsaturated fatty acides reduces pathological retinal angiogenesis. Nat Med, 2007, 13: 868-873.
|
|
20 Kang JX, Wang J, Wu L, et al. Transgenic mice: Fat-1 mice convert n-6 to n-3 fatty acids[J]. Nature, 2004, 427: 504.
|